Outcomes of Transcatheter Edge-to-Edge Repair, Surgical and Medical Therapy in Combined Mitral and Tricuspid Regurgitation

Merdad, Anas; Fam, Neil; Connelly, Kim A.; Peterson, Mark D.; Moe, Gordon W.; Hassanin, Magdi; Burke, Lucas; Bagai, Akshay; Ali, Faeez Mohamad; Ong, Géraldine

doi:10.1016/j.jcin.2021.09.041

Cited by 3 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This allows for an improvement in effective systolic volume of the left ventricle in patients with combined mitral and TR treatment, if the right-sided circulation is capable of supplying this additional stroke volume. 8 , 12 , 13 …”

Section: Discussionmentioning

confidence: 99%

Percutaneous mitral and tricuspid edge-to-edge repair as a bridge therapy to heart transplantation in advanced heart failure secondary to human immunodeficiency virus: a case report

Aquino-Bruno,

Andrade-Cuellar,

Morales-Portano

et al. 2023

European Heart Journal - Case Reports

View full text Add to dashboard Cite

Background Patients with end-stage heart failure (HF) and severe pulmonary hypertension (PH) are not eligible for heart transplant due to high mortality risk. Percutaneous interventions as edge-to-edge repair of the mitral/tricuspid valves are a safe and effective therapy as a bridge for transplantation in patients who have contraindications to heart transplantations (HTs). Case summary A 44-year-old man with a previous diagnosis of infection by human immunodeficiency virus (HIV) was admitted at the emergency room for exertional dyspnoea. He was diagnosed with a decompensated heart failure with reduced ejection fraction (HFrEF), severe mitral and tricuspid regurgitation, and high probability of PH. He presented poor response to guided medical treatment, even after implantable cardiac resynchronization therapy defibrillator (CRT-D). He was listed for a cardiac transplant, but after right catheterization, he was not an ideal candidate for transplantation, so it was decided to undergo percutaneous mitral and tricuspid edge-to-edge repair as a bridge to transplantation. The post-operative course was uneventful, with significant improvement in New York Heart Association functional class. The patient underwent a successful heart transplant 10 months after the procedure. Discussion In patients with advanced HF due to HIV, HT is an adequate treatment option. When there are functional mitral and tricuspid regurgitation and severe PH, despite optimal treatment according to current guidelines, percutaneous mitral and tricuspid repair therapy appears to be safe and effective for control of severe PH as a bridge measure for cardiac transplantation.

show abstract

Section: Discussionmentioning

confidence: 99%

Percutaneous mitral and tricuspid edge-to-edge repair as a bridge therapy to heart transplantation in advanced heart failure secondary to human immunodeficiency virus: a case report

Aquino-Bruno,

Andrade-Cuellar,

Morales-Portano

et al. 2023

European Heart Journal - Case Reports

View full text Add to dashboard Cite

show abstract

“… 58 , 59 Consequently, managing concomitant MR and TR within the surgical population is more straightforward with the ability to simultaneously repair both valves. 58 , 59 , 60 , 61 , 62 However, until recent FDA approval of transcatheter treatments for the tricuspid valve, transcatheter therapy was limited to isolated mitral treatment which is likely less effective than dual-valve therapy. 60 , 61 , 62 Fortunately, the mounting data in favor of TTVI, specifically tricuspid transcatheter edge-to-edge repair (t-TEER), may lead to the approval of commercially available devices soon.…”

Section: Mitral Regurgitation and Tricuspid Regurgitationmentioning

confidence: 99%

“… 58 , 59 , 60 , 61 , 62 However, until recent FDA approval of transcatheter treatments for the tricuspid valve, transcatheter therapy was limited to isolated mitral treatment which is likely less effective than dual-valve therapy. 60 , 61 , 62 Fortunately, the mounting data in favor of TTVI, specifically tricuspid transcatheter edge-to-edge repair (t-TEER), may lead to the approval of commercially available devices soon. 44 , 45 Transcatheter mitral and tricuspid valve repair (TMTVR) should improve outcomes in this patient cohort, as suggested in retrospective literature.…”

Section: Mitral Regurgitation and Tricuspid Regurgitationmentioning

confidence: 99%

Multiple Valvular Heart Disease in the Transcatheter Era: A State-of-the-Art Review

Basman,

Landers,

Dudiy

et al. 2024

Structural Heart

View full text Add to dashboard Cite

Concomitant Transcatheter Edge-to-Edge Treatment of Secondary Tricuspid and Mitral Regurgitation

Sisinni

Taramasso

Praz

et al. 2023

JACC: Cardiovascular Interventions

View full text Add to dashboard Cite

Outcomes of Transcatheter Edge-to-Edge Repair, Surgical and Medical Therapy in Combined Mitral and Tricuspid Regurgitation

Cited by 3 publications

References 4 publications

Percutaneous mitral and tricuspid edge-to-edge repair as a bridge therapy to heart transplantation in advanced heart failure secondary to human immunodeficiency virus: a case report

Percutaneous mitral and tricuspid edge-to-edge repair as a bridge therapy to heart transplantation in advanced heart failure secondary to human immunodeficiency virus: a case report

Multiple Valvular Heart Disease in the Transcatheter Era: A State-of-the-Art Review

Concomitant Transcatheter Edge-to-Edge Treatment of Secondary Tricuspid and Mitral Regurgitation

Contact Info

Product

Resources

About